Note to our followers: Our nearly 13-year run of daily publication of new content on HealthNewsReview.org came to a close at the end of 2018. Publisher Gary Schwitzer and other contributors may post new articles periodically. But all of the 6,000+ articles we have published contain lessons to help you improve your critical thinking about health care interventions. And those will be still be alive on the site for a couple of years.

More Pfizer Pfun

The Alt_Mentalities website published a piece, “Lemons into Lemonade: How an off-label marketing fine can be good for business,” tracking Pfizer’s journey through fines for off-label marketing of Neurontin and, later, for Lyrica and other drugs. Punchline question in the piece:

“Was taking the hit for off-label marketing in 2004 all part of a plan to boost sales for forthcoming Lyrica, now the star performer in the Pfizer portfolio?”

And on his Skeptical Sleuth blog for Psychology Today, James C. Coyne, PhD, writes:  “Screening Cancer Patients for Distress: No evidence that screening improves patient outcomes,” – regarding another Pfizer initiative. He begins:

“Pfizer gave a psychologist at the Moffitt Cancer Center in Florida over $10 million to study whether oncology professionals’ attention to cancer patients’ psychological distress could effectively be monitored through chart review. Why this extraordinary amount of money? Is it a matter of generous, unrestricted philanthropy, or is there a clever marketing strategy behind it?”

 

 

You might also like

Comments

Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.

Comments are closed.